

4



1636

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on December 9, 2003

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Examining Group 1636

Patent Application

Docket No. GJE-74

Serial No. 09/913,443

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Celine X. Qian
Art Unit : 1636
Applicant : Jack Price
Serial No. : 09/913,443
Filed : August 14, 2001
Confirm. No. : 9647
For : Transplantation of Haematopoietic Cells

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
DEC 16 2003
TECHNOLOGY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 AND 1.98


Sir:

In accordance with 37 CFR § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the Notice of Allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065

The applicant respectfully asserts that the substantive provisions of 37 CFR §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,


Glenn P. Ladwig
Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

RECEIVED
DEC 16 2003
TECH CENTER 1600/2900

GPL/mv

Attachments: Form PTO/SB/08 (4 pages); copies of references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/913,443
Filing Date	August 14, 2001
First Named Inventor	Jack Price
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	GJE-74

Sheet

1

of

4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2003/0203483 A1	10-03-2003	Seshi	All
	U2	US-2003/0147873 A1	08-07-2003	Sinden et al.	All
	U3	US-2002/0146821 A1	10-10-2002	Sanchez-Ramos et al.	All
	U4	US-2002/0123143 A1	09-05-2002	Toma et al.	All
	U5	US-2002/0028510 A1	03-07-2002	Sanberg et al.	All
	U6	US-2001/0001662 A1	05-24-2001	Sinden et al.	All
	U7	US-6,569,421 B2	05-27-2003	Hodges	All
	U8	US-6,465,215 B1	10-15-2002	Price et al.	All
	U9	US-6,399,384 B1	06-04-2002	Jat	All
	U10	US-6,200,806 B1	03-13-2001	Thomson	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 03/029432 A2	04-10-2003	Univ. of South Florida	All	
	F2	WO 01/94541 A2	12-13-2001	Univ. of South Florida	All	
	F3	WO 01/66698 A1	09-13-2001	Cryo-Cell Int'l Inc.	All	
	F4	WO 97/10329 A1	03-20-1997	Inst. of Psychiatry	All	
	F5	WO 89/09816 A1	10-19-1989	Mass. Inst. Tech.	All	
	F6					
	F7					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/913,443
				Filing Date	August 14, 2001
				First Named Inventor	Jack Price
				Art Unit	1636
				Examiner Name	Celine X. Qian
Sheet	2	of	4	Attorney Docket Number	GJE-74

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-6,197,585 B1	03-06-2001	Stringer	All
	U2	US-5,958,767	09-28-1999	Snyder et al.	All
	U3	US-5,851,832	12-22-1998	Weiss et al.	All
	U4	US-5,753,491	05-19-1998	Major et al.	All
	U5	US-5,580,777	12-03-1996	Bernard et al.	All
	U6	US-5,270,191	12-14-1993	McKay et al.	All
	U7				
	U8				
	U9				
	U10				


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no responses are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/913,443
Filing Date	August 14, 2001
First Named Inventor	Jack Price
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	GJE-74

Sheet	3	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CEPKO, C.L. "Immortalization of Neural Cells Via Retrovirus-Mediated Oncogene Transduction" <i>Ann. Rev. Neurosci.</i> , 1989, 12:47-65.	
	R2	CHEN, J. <i>et al.</i> "Intravenous Administration of Human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats" <i>Stroke</i> , 2001, 32:2682-2688.	
	R3	CRYSTAL, R.G. "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" <i>Science</i> , 1995, 270:404-410.	
	R4	DEONARAIN, M.P. "Ligand-targeted receptor-mediated vectors for gene delivery" <i>Exp. Opin. Ther. Patents</i> , 1998, 8(1):53-69.	
	R5	GRAY, J.A. <i>et al.</i> "Prospects for the clinical application of neural transplantation with the use of conditionally immortalized neuroepithelial stem cells" <i>Phil. Trans. R. Soc. Lond. B</i> , 1999, 354:1407-1421.	
	R6	KOPEN, G.C. <i>et al.</i> "Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains" <i>Proc. Natl. Acad. Sci USA</i> , September 1999, 96:10711-10716.	
	R7	MCKAY, R. <i>et al.</i> "Mechanisms Regulating Cell Number and Type in the Mammalian Central Nervous System" Cold Spring Harbor Symposia on Quantitative Biology, 1990, 55:291-301.	
	R8	MCKAY, R. <i>et al.</i> "Immortalized stem cells from the central nervous system" <i>C.R. Acad. Sci. Paris, Sciences De La Vie</i> , 1993, 316:1452-1457.	
	R9	MILLER, N. and R. VILE "Targeted vectors for gene therapy" <i>FASEB J.</i> , 1995, 9:190-199.	
	R10	NETTO, C.A. <i>et al.</i> "Foetal grafts from hippocampal region superior alleviate ischaemic-induced behavioral deficits" <i>Behav. Brain. Res.</i> , 1993, 58:107-112.	
	R11	OKABE, S. <i>et al.</i> "Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro" <i>Mech. Devel.</i> , 1996, 59:89-102.	
	R12	RASHID-DOUBELL, F. <i>et al.</i> "Effects of Basic Fibroblast Growth Factor and Gamma Interferon on Hippocampal Progenitor Cells Derived From the H-2Kb-tsA58 Transgenic Mouse" <i>Gene Therapy</i> , 1994, 1(Supp. 1):S63.	
	R13	SANBERG, P.R. and A.E. WILLING "Cellular Therapeutic Approaches for Neurodegenerative Disorders" <i>Proceedings of the 1998 Miami Biotechnology Symposium</i> , February 7-11, 1998, 38:139-142.	

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 39 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/913,443
Filing Date	August 14, 2001
First Named Inventor	Jack Price
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	GJE-74

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	SANCHEZ-RAMOS, J.R. <i>et al.</i> "Expression of Neural Markers in Human Umbilical Cord Blood" <i>Exp. Neurol.</i> , 2001, 171:109-115.	
	R15	SCHEFFLER, B. <i>et al.</i> "Marrow-mindedness: a perspective on neurogenesis" <i>Trends Neurosci.</i> , 1999, 22:348-357.	
	R16	SINDEN, J.D. <i>et al.</i> "Recovery of Spatial Learning by Grafts of a Conditionally Immortalized Hippocampal Neuroepithelial Cell Line Into the Ischaemia-Lesioned Hippocampus" <i>Neuroscience</i> , 1997, 81(3):599-608.	
	R17	VIRLEY, D. <i>et al.</i> "Primary CA1 and conditionally immortal NHP36 cell grafts restore conditional discrimination learning and recall in marmosets after excitotoxic lesions of the hippocampal CA1 field" <i>Brain</i> , 1999, 122:2321-2335.	
	R18	WHITEMORE, S.R. <i>et al.</i> "Isolation and Characterization of Conditionally Immortalized Astrocyte Cell Lines Derived From Adult Human Spinal Cord" <i>GLIA</i> , 1994, 10:221-226.	
	R19	WYLLIE, F.S. <i>et al.</i> "A Phenotypically and Karyotypically Stable Human Thyroid Epithelial Line Conditionally Immortalized by SV40 Large T Antigen" <i>Cancer Res.</i> , 1992, 52:2938-2945.	
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 39 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.